Slides
Page 1
Investor Presentation Q2FY27 27-10-2026 1
Page 2
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes “g” and “generic” used interchangeably indicate the generic versions of the named brand drugs. Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country. The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals. Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional. 2
Page 3
Consistent Sequential Growth in Revenue and EBITDA Reflecting Sustained Business Momentum 1. Market data as per IQVIA MAT Aug’26 Business Performance Snapshot Revenue EBITDA PAT INR 7,404 Cr INR 1,388 Cr INR 878 Cr $ 172 MnINR 3,516 Cr 12% $ 123 Mn Highest-ever quarterly revenue Q2FY27 Q2FY27 (YoY) One India North America One Africa Emerging Markets & Europe 3 18.7% Margin 11.9% Margin Received U.S. FDA approval for gAdvair Diskus SA private growing 1.3x faster than the market1 Resilient performance amid geopolitical uncertainties $ 101 Mn
Page 4
1. One India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Opex including depreciation Revenues INR 7,404 Cr EBITDA 1,388 Cr Q2FY27 (INR Cr) Q2FY26 (INR Cr) Total Revenue from Operations 7,404 7,589 EBITDA 1,388 1,895 EBITDA % 18.7% 25.0% PAT 878 1,351 PAT % 11.9% 17.8.% Q2FY27 (Consolidated)Revenue1 Break-up One India, 48% North America, 22% One Africa, 16% Emerging markets and Europe, 13% API and Others, 1% R&D2 INR 423 Cr | 5.7% of revenue 4 Financial Performance : Q2FY27
Page 5
Branded Prescription ❖ Cipla maintained #2 rank in overall chronic segment2 ❖ Continued portfolio expansion with recent launch of Yurpeak, Duolin Syncrobreathe, Revesmart and Rizontem ❖ Double-digit growth2 in chronic therapies like Respiratory, Cardiac, Urology, Anti-diabetes, and Dermatology Trade Generics ❖ Delivered a strong double-digit QoQ growth ❖ 3 Brands with TTM revenue of > INR 100 Cr and 5 Brands with TTM revenue of INR 50 Cr to INR 100 Cr ❖ 18 new launches in Q2FY27 Consumer Health ❖ Anchor and transitioned brands continuing to grow bigger ❖ Haircare delivered strong double- digit growth ❖ Omnigel, Nicotex, Prolyte and Cipladine maintained their leadership positions in the market 1. One India includes Rx, Gx and CHL | 2. Market data as per IQVIA YTD Sep’26 5 Highest-ever quarterly revenue of INR 3,516 Cr One India1 : Building a Sustainable Legacy for Enduring Growth
Page 6
1. Market data as per IQVIA YTD Sep’26 | 2. Market data as per IQVIA MAT Sep’26 23 Brands IPM2 Brands in Top 300 ranks Key Market Highlights IPM2 Brands with revenue > INR 100 Cr 7 Therapies With IPM2 Top 5 ranks 36 Brands 1000+ Cr Foracort Biggest Respiratory Brand in IPM2 6 Largest pharma company by volume (units) in market2 Our in-house brand franchise, Dytor2, has scaled to over INR 800 Cr+ India Rx : Strengthening Our Journey with Strategic Therapeutic Focus Respiratory supremacy, with Cipla's brand franchises occupying all top 5 spots2 Steady Uptake in Key Therapies1 Growth (%) Rank 1st 2nd 7th 8th 11th 16% 20% 50% 11% 11% Dermatology Cardiac Anti-diabetic Urology Respiratory
Page 7
7 Recent Launches Demonstrate Strong Early Momentum Across Priority Therapies Respiratory Critical Care India’s first once-daily nebulized bronchodilator for management of chronic obstructive pulmonary disease Galvus DM [ Vildagliptin SR+ Dapagliflozin+ Metformin SR] is indicated for the treatment of patients with type 2 diabetes mellitus. Dytor E FDC [Torsemide+Eplerenone] is indicated in the Patients with Congestive Heart Failure. Rizontem (Aztreonam and Avibactam powder for concentrate for solution for Infusion) is indicated in treatment of complicated Urinary Tract Infection including pyelonephritis, Hospital-acquired Pneumonia including ventilator- associated pneumonia and Complicated intra- abdominal infection Diabetology Cardiology Disclaimer: Product images and descriptions are included for information purposes only and do not constitute promotional or a dvertising material. Please refer to the approved prescribing information/package insert for complete product details.
Page 8
Strategic Alliances during the Quarter Bispecific HER2 ADC 8 Pembrolizumab Biosimilar ❑ Exclusive U.S. licensing and supply partnership with Qilu Pharmaceutical for QL2107, a Keytruda biosimilar. ❑ Qilu will lead development, regulatory registration and supply, while Cipla will be responsible for U.S. commercialization. ❑ Strengthens Cipla’s oncology-focused biosimilars portfolio and supports improved access to advanced biologic therapies, subject to regulatory approval ❑ Exclusive licensing agreement with CTTQ (SinoBiopharma Group) for TQB2102 across India, South Africa and five other emerging markets. ❑ Advanced bispecific HER2 ADC with a differentiated 3-in-1 mechanism and potential safety/efficacy advantages. ❑ Strengthens Cipla’s presence in ADCs and immunotherapy, targeting HER2-low breast cancer, ~50% of breast cancer cases in India.
Page 9
9 9 Cold and Cough Hydration Pain Relief Smoking Cessation Respi OTC One India One Africa Consumer Brands in One India Revenue : INR 427 Cr Consumer Brands in South Africa Revenue : ZAR 463 Mn Note:- Above numbers exclude sales of wellness brands through prescription channel Respi OTC Skin Infection Cold and Cough Cold and Flu Q2 FY27 : Global Consumer Wellness Franchise Pain Management
Page 10
Key Business Highlights – Q2FY27 ▪ gProventil ranked No. 1 with total market1 share at 22% (50 million+ inhaler units supplied to the U.S. market cumulatively) ▪ Received U.S. FDA approval for gAdvair Diskus across all three strengths (100/50, 250/50, and 500/50 mcg), an important milestone for our U.S. respiratory business 10 Recent New Launches North America : Adapting to Evolving Business Dynamics 1. Market data as per IQVIA week ending 25th September 2026 (No. 1 rank in overall U.S. Albuterol MDI market) Dapagliflozin gVentolin Nintedanib Liraglutide
Page 11
1. PEPFAR approved ANDAs can be commercialised in US 191 Approved ANDAs & NDAs 44 Tentatively Approved ANDAs & NDAs 46 Under Approval ANDAs & NDAs 281 Total ANDAs & NDAs 11 106 19 37 9 23 3 69 4 7 2 2 Approved ANDAs & NDAs Tentatively Approved ANDAs & NDAs Under Approval ANDAs & NDAs Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs 1 ANDA & NDA Portfolio & Pipeline (As on 30th September 2026)
Page 12
1. One Africa - South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Market data as per IQVIA MAT Aug’26 Growth 1.3X2 Faster growth than market for private business 6 new launches Across multiple therapies in Q2 FY27 ▪ Healthy performance across key therapies like G.U. system + Sex Hormones, Nervous System and Dermalogicals ▪ 10 brands with MAT market revenue > 100 Mn ZAR ▪ Highest number of brands in top 30 (6), top 50 (11) and top 100 (20) within generics segment ▪ Private business revenue of ZAR 1,294 Mn for Q2FY27 SA Key Highlights2 12 Market Segment 2 Rank Share Cipla Growth Market Growth South Africa Prescription 2 8.9% 9.9% 6.0% South Africa OTC 3 7.7% 0.3% 3.3% South Africa Overall 3 8.5% 6.5% 5.0% 80 80 23 12 11 10 21 21 Q2FY26 Q2FY27 SA Private SA Tender North Africa Others (SSA & CGA) One Africa1 : South Africa Private Growing Faster than the Market
Page 13
• * Based on normalization of IREC volumes progress YTD Aug’26 ** Decrease in the Central Electricity Authority (CEA) emission factor in FY 26-27 versus FY 23-24 • CMM=CIPLA MEDPRO MANUFACTURING PTY LTD, South Africa 13 Achievement CIPLA PHARMACEUTICALS LIMITED D8, Kurkumbh has achieved Silver Certification under LEED v4 BD+C Bronze Medal for year 2026 in EcoVadis, ranking among the top 35% of globally rated companies Aspects Goals FY 2029-30 Progress Renewable Electricity Share 80% renewable electricity share for India manufacturing 77%* GHG Emissions (Scope 1 & 2) • 30% absolute reduction (Scope 1-Energy based & Scope-2) from baseline of FY2023-24 for Global Cipla 44%** • Build capacity infrastructure for green propellants used in MDI Ongoing pilot project Water Neutrality Water Neutral for India manufacturing Achieved 2.6 times water positivity in FY26. Next Certification- Mar’27 Zero Waste to Landfill Maintain ZWL status for Cipla India and expand coverage for ZWL to overseas sites for USA and One Africa CMM Certified- July’26; India Manufacturing Certification- Mar’27 AMR One antibiotic product per Cipla India site certified as per AMR manufacturing standard Certification for 2 Sites- Mar’27 Occupational Health and Safety Zero fatality in manufacturing operations 0 DEI Representation of women in Cipla Leadership Group at 20% or above from a baseline year of FY25 15.8% Responsible Procurement Minimum 80% of critical Indian suppliers to comply with Cipla ESG framework Preparation of supplier assessment ESG framework Environment Social Governance Progress on ESG goals (India Manufacturing Operations) : Q2FY27
Page 14
INR Cr 14 Consolidated Profit and Loss Statement Summary Note : Figures have been rounded-off Particulars Q2FY27 Q2FY26 Revenue from sale of products 7,368 7,447 Other operating income 36 142 Income from operations 7,404 7,589 Material cost 2,634 2,498 Employee benefits expense 1,475 1,315 Other expenses 1,908 1,882 Total expenses 6,016 5,695 Finance costs 17 13 Depreciation, impairment and amortisation expense 345 297 Other income 151 269 Profit before exceptional items and tax 1,177 1,854 Exceptional Items - - Profit before tax 1,177 1,854 Tax expenses 321 500 Share of associate -5 - Profit for the period 852 1,353 Non-controlling interest -26 2 Profit for the period attributable to shareholders 878 1,351
Page 15
INR Cr 15 Consolidated Balance Sheet #Total debt includes lease liabilities and borrowings | *Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances |Figures have been rounded-off Key Balance Sheet Items Sep-26 Sep-25 Equity 35,522 33,025 Total Debt# 699 467 Inventory 6,778 6,160 Cash and Cash Equivalents* 10,522 10,368 Trade Receivables 6,000 6,902 Trade Payables 3,266 3,035 Net Tangible Assets 8,266 6,996 Goodwill and Intangibles 7,107 5,374
Page 16
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 Diksha Maheshwari Investor.Relations@cipla.com For more information, please visit www.cipla.com 16